Literature DB >> 33669565

Association of Sepsis Mortality with Specific Cancer Sites and Treatment Type: The Multiethnic Cohort Study.

Yurii B Shvetsov1, Mari H Ogino1, Natalija Glibetic1, Chloe B Asato1, Lynne R Wilkens1, Loïc Le Marchand1, Michelle L Matter1.   

Abstract

Sepsis is a severe dysregulated immune response to infection. Sepsis deaths represent 9% of cancer deaths in the U.S. Evidence of the effect of specific cancer sites on sepsis mortality risk remains limited, and no research has evaluated the effect of cancer treatment on the risk of sepsis death. We examined whether cancer sites and treatments differentially affect the risk of sepsis death compared to other-cause mortality, among the 94,784 Hawaii participants in the Multiethnic Cohort, including 29,255 cancer cases, using competing risk Cox proportional hazards regression. Cancer diagnosis at any site was associated with similar increases in sepsis and non-sepsis mortality risk (HR: 3.39 and 3.51, resp.). Colorectal cancer differentially affected the risk of sepsis and non-sepsis mortality with a 40% higher effect on the risk of sepsis death compared with non-sepsis mortality (RRR: 1.40; 95% CI: 1.14-1.72). Lung cancer was associated with a significantly lower increase in sepsis compared to non-sepsis mortality (HR: 1.22 and 3.0, resp.; RRR: 0.39). Radiation therapy had no effect on sepsis mortality but was associated with higher risk of non-sepsis mortality (HR: 0.90 and 1.16, resp.; RRR: 0.76), whereas chemotherapy was associated with higher risk of both sepsis and non-sepsis mortality (HR: 1.31 and 1.21, resp.). We conclude that the risk of sepsis-related mortality is differentially affected by cancer sites and treatments. These associations were consistent across sexes and ethnic groups.

Entities:  

Keywords:  cancer; cancer treatment; mortality; sepsis

Year:  2021        PMID: 33669565      PMCID: PMC7922684          DOI: 10.3390/jpm11020146

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  24 in total

1.  Sepsis and endothelial permeability.

Authors:  Warren L Lee; Arthur S Slutsky
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

Review 2.  Epidemiology of sepsis: an update.

Authors:  D C Angus; R S Wax
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

Review 3.  Severe sepsis and septic shock.

Authors:  Derek C Angus; Tom van der Poll
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

4.  The epidemiology of sepsis in patients with malignancy.

Authors:  Pajman A Danai; Marc Moss; David M Mannino; Greg S Martin
Journal:  Chest       Date:  2006-06       Impact factor: 9.410

Review 5.  Effect of new antimicrobial agents on the ecological balance of human microflora.

Authors:  Mamun-Ur Rashid; Andrej Weintraub; Carl Erik Nord
Journal:  Anaerobe       Date:  2011-12-02       Impact factor: 3.331

6.  A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics.

Authors:  L N Kolonel; B E Henderson; J H Hankin; A M Nomura; L R Wilkens; M C Pike; D O Stram; K R Monroe; M E Earle; F S Nagamine
Journal:  Am J Epidemiol       Date:  2000-02-15       Impact factor: 4.897

Review 7.  Effect of antimicrobial agents on the ecological balance of human microflora.

Authors:  A Sullivan; C Edlund; C E Nord
Journal:  Lancet Infect Dis       Date:  2001-09       Impact factor: 25.071

8.  Statistical methods for studying disease subtype heterogeneity.

Authors:  Molin Wang; Donna Spiegelman; Aya Kuchiba; Paul Lochhead; Sehee Kim; Andrew T Chan; Elizabeth M Poole; Rulla Tamimi; Shelley S Tworoger; Edward Giovannucci; Bernard Rosner; Shuji Ogino
Journal:  Stat Med       Date:  2015-12-01       Impact factor: 2.373

Review 9.  Immunomodulatory effects of quinolones.

Authors:  Axel Dalhoff; Itamar Shalit
Journal:  Lancet Infect Dis       Date:  2003-06       Impact factor: 25.071

Review 10.  The Changing Epidemiology and Definitions of Sepsis.

Authors:  Jordan A Kempker; Greg S Martin
Journal:  Clin Chest Med       Date:  2016-03-23       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.